Biomarkers for increased risk of drug-induced osteonecrosis of the jaw
AssigneeSevere Adverse Event (Sae) Consortium
InventorAris FLORATOS
Life of this patent
Estimating the term…
Abstract
The present disclosure provides a method for predicting the risk of a patient for developing adverse drug reactions, particularly drug-induced osteonecrosis of the jaw (ONJ). The disclosure also provides a method of identifying a subject afflicted with, or at risk of, developing ONJ. In some aspects, the methods comprise analyzing at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with, or at risk of, developing ONJ.
Claims2
A method of identifying a subject afflicted with, or at risk of, developing osteonecrosis of the jaw (ONJ), the method comprising:
- (a) obtaining a nucleic acid-containing sample from the subject;
- and
- (b) analyzing the sample to detect the presence of at least one genetic marker, wherein the presence of the at least one genetic marker indicates that the subject is afflicted with, or at risk of, developing ONJ.
Dependencies are inferred from the claim text.